BR9913084A - Agente antitrombótico e anticorpo monoclonal com fator antivon willebrand humanizado - Google Patents

Agente antitrombótico e anticorpo monoclonal com fator antivon willebrand humanizado

Info

Publication number
BR9913084A
BR9913084A BR9913084-0A BR9913084A BR9913084A BR 9913084 A BR9913084 A BR 9913084A BR 9913084 A BR9913084 A BR 9913084A BR 9913084 A BR9913084 A BR 9913084A
Authority
BR
Brazil
Prior art keywords
willebrand factor
monoclonal antibody
humanized anti
antithrombotic agent
von willebrand
Prior art date
Application number
BR9913084-0A
Other languages
English (en)
Inventor
Man Sung Co
Maximiliano Vasquez
Original Assignee
Ajinomoto Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Kk filed Critical Ajinomoto Kk
Publication of BR9913084A publication Critical patent/BR9913084A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Patente de Invenção: <B>"AGENTE ANTITROMBóTICO E ANTICORPO MONOCLONAL COM FATOR ANTI-VON WILLEBRAND HUMANIZADO"<D>. Agentes antitrombóticos contendo anticorpos humanizados que se ligam ao fator von Willebrand.
BR9913084-0A 1998-08-19 1999-08-19 Agente antitrombótico e anticorpo monoclonal com fator antivon willebrand humanizado BR9913084A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/136,315 US6228360B1 (en) 1998-08-19 1998-08-19 Antithrombotic agent and humanized anti-von Willebrand factor monoclonal antibody
PCT/US1999/016724 WO2000010601A1 (en) 1998-08-19 1999-08-19 Antithrombotic agent and humanized anti-von willebrand factor monoclonal antibody

Publications (1)

Publication Number Publication Date
BR9913084A true BR9913084A (pt) 2001-05-08

Family

ID=22472317

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9913084-0A BR9913084A (pt) 1998-08-19 1999-08-19 Agente antitrombótico e anticorpo monoclonal com fator antivon willebrand humanizado

Country Status (17)

Country Link
US (4) US6228360B1 (pt)
EP (1) EP1112085B1 (pt)
JP (1) JP4590734B2 (pt)
KR (1) KR100693260B1 (pt)
CN (1) CN1259972C (pt)
AT (1) ATE476989T1 (pt)
AU (1) AU766500B2 (pt)
BR (1) BR9913084A (pt)
CA (1) CA2340466A1 (pt)
DE (1) DE69942668D1 (pt)
HU (1) HUP0103573A3 (pt)
IL (2) IL141158A0 (pt)
NO (1) NO20010747L (pt)
NZ (1) NZ509536A (pt)
RU (1) RU2223785C2 (pt)
WO (1) WO2000010601A1 (pt)
ZA (1) ZA200100939B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6228360B1 (en) 1998-08-19 2001-05-08 Ajinomoto Co., Inc. Antithrombotic agent and humanized anti-von Willebrand factor monoclonal antibody
GB0031448D0 (en) * 2000-12-22 2001-02-07 Leuven K U Res & Dev Inhibition of the vWF-collagen interaction by anti-human vWF monoclonal antibody (82D6A3) results in abolition of in vivo arterial platelet thrombus formation
AU2002335815A1 (en) * 2001-10-16 2003-04-28 Rxkinetix, Inc. High-concentration protein formulations and method of manufacture
JP2005298336A (ja) * 2002-01-29 2005-10-27 Ajinomoto Co Inc 炎症性疾患治療用薬剤
WO2004011030A1 (ja) * 2002-07-29 2004-02-05 Ajinomoto Co., Inc. 血小板減少症治療用医薬組成物
ATE512364T1 (de) * 2002-08-07 2011-06-15 Ablynx Nv Modulation der blutplättchen-adhäsion basierend auf dem oberflächen-exponierten beta-switch loop des blutplättchen-glycoproteins ib-alpha
EP1587838B1 (en) 2003-01-10 2015-04-15 Ablynx N.V. Therapeutic polypeptides, homologues thereof, fragments thereof and their use in modulating platelet-mediated aggregation
CA2559280A1 (en) * 2004-03-15 2005-09-29 Biogen Idec Ma Inc. Methods and constructs for expressing polypeptide multimers in eukaryotic cells using alternative splicing
EP1755642B1 (en) * 2004-04-15 2010-01-13 Athera Biotechnologies Ab Annexin v for preventing plaque rupture
CA2579374A1 (en) * 2004-09-07 2006-03-30 Archemix Corp. Aptamers to von willebrand factor and their use as thrombotic disease therapeutics
US20090202986A1 (en) * 2004-10-22 2009-08-13 Huse William D Methods of optimizing antibody variable region binding affinity
WO2006074947A2 (en) * 2005-01-14 2006-07-20 Ablynx N.V. METHODS AND ASSAYS FOR DISTINGUISHING BETWEEN DIFFERENT FORMS OF DISEASES AND DISORDERS CHARACTERIZED BY THROMBOCYTOPENIA AND/OR BY SPONTANEOUS INTERACTION BETWEEN VON WILLEBRAND FACTOR (vWF) AND PLATELETS
KR101414438B1 (ko) * 2005-05-20 2014-07-10 아블린쓰 엔.브이. 폰 빌레브란트 인자에 대한 단일 도메인 ｖｈｈ 항체
AR070141A1 (es) * 2008-01-23 2010-03-17 Glenmark Pharmaceuticals Sa Anticuerpos humanizados especificos para el factor von willebrand
JP2011518772A (ja) * 2008-03-21 2011-06-30 アブリンクス エン．ヴェー． フォンウィルブランド因子特異的結合因子及びこれらに関する使用方法
US9229010B2 (en) 2009-02-06 2016-01-05 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2010091231A1 (en) * 2009-02-06 2010-08-12 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN102532316B (zh) * 2010-12-24 2014-06-18 神州细胞工程有限公司 一种抗vWF单克隆抗体及其应用
WO2015158851A1 (en) * 2014-04-16 2015-10-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies for the prevention or the treatment of bleeding episodes

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB9020282D0 (en) * 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation
DE69233482T2 (de) * 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US5777085A (en) * 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
ZA93779B (en) * 1992-02-06 1993-08-05 Schering Corp Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5.
EP0625200B1 (en) * 1992-02-06 2005-05-11 Chiron Corporation Biosynthetic binding protein for cancer marker
ATE236993T1 (de) * 1994-11-30 2003-04-15 Ajinomoto Kk Antithrombose mittel und gegen den von willebrand-faktor gerichtete monoklonale antikörper
US6228360B1 (en) * 1998-08-19 2001-05-08 Ajinomoto Co., Inc. Antithrombotic agent and humanized anti-von Willebrand factor monoclonal antibody

Also Published As

Publication number Publication date
RU2223785C2 (ru) 2004-02-20
AU766500B2 (en) 2003-10-16
EP1112085A4 (en) 2002-11-20
KR100693260B1 (ko) 2007-03-13
US20030180293A1 (en) 2003-09-25
US20030064068A1 (en) 2003-04-03
DE69942668D1 (de) 2010-09-23
JP2002523379A (ja) 2002-07-30
HUP0103573A2 (hu) 2002-01-28
KR20010072749A (ko) 2001-07-31
US6613328B2 (en) 2003-09-02
ZA200100939B (en) 2001-09-03
CN1259972C (zh) 2006-06-21
NO20010747D0 (no) 2001-02-14
JP4590734B2 (ja) 2010-12-01
HUP0103573A3 (en) 2003-09-29
IL141158A (en) 2006-04-10
AU5668099A (en) 2000-03-14
NZ509536A (en) 2002-11-26
EP1112085A1 (en) 2001-07-04
CN1311691A (zh) 2001-09-05
CA2340466A1 (en) 2000-03-02
US6228360B1 (en) 2001-05-08
IL141158A0 (en) 2002-02-10
NO20010747L (no) 2001-04-03
US7138116B2 (en) 2006-11-21
US7311913B2 (en) 2007-12-25
US20050197494A1 (en) 2005-09-08
ATE476989T1 (de) 2010-08-15
WO2000010601A1 (en) 2000-03-02
EP1112085B1 (en) 2010-08-11

Similar Documents

Publication Publication Date Title
BR9913084A (pt) Agente antitrombótico e anticorpo monoclonal com fator antivon willebrand humanizado
ES2177632T3 (es) Purificacion de anticuerpos.
DE60142342D1 (de) Antikörper gegen doppelintegrinen, zusammensetzungen, verfahren und verwendungen
BR9707049A (pt) Agentes anticoagulantes utilizáveis no tratamento de trombose
DE69938054D1 (de) Antikörpervarianten mit höheren bindungsaffinitäten im vergleich zu parentalen antikörpern
DE69227456D1 (de) Nachweis von kollagenabbau -i(in vivo)
DE3482905D1 (de) Monoklonale antikoerper gegen lungenkrebs des &#34;nicht-kleine-zellen&#34;-typs.
DE3580382D1 (de) Monoklonale antikoerper gegen alpha-2 interferon und hybridomas, die solche antikoerper produzieren.
ATE230418T1 (de) Monoklonaler antikörper gegen das humane mx- protein mxa
ATE77243T1 (de) E87ag-antigen des pseudomonas aeruginosa, monoklonale antikoerper dagegen und hybridom.
DE3888604D1 (de) Monoklonale Antikörper gegen Antithrombinbindende Substanz und seine Verwendungen.
DE69527868D1 (de) Monoklonaler Antikörper gegen den tumorzytotoxischen Faktor II (TCF-II)
DE68917797D1 (de) Gegen menschliches Fibrinopepid A spezifische monoklonale Antikörper.
ATE263784T1 (de) Anti-megakaryozyten monoklonaler antikörper 97a6
EP0554670A3 (en) Specific antibodies against activated platelets, their production and applications in diagnostics and therapeutics
ATE324380T1 (de) Monoklonale antikörper gegen s100
DE69020315T2 (de) Monoklonaler antikörper gegen c-reaktives protein.
DE69333683D1 (de) Antikörper-testbesteck zur bestimmung von amylin
DK0889907T3 (da) Monoklonale antistoffer, som binder humant væksthormon (hGH)
NO985281D0 (no) Monoklonalt antihumant MP52-antistoff
HUP9903273A3 (en) Anti-human mp52 monoclonal antibody
FI956041A (fi) Kompositiot ja diagnostiset menetelmät, joissa käytetään monoklonaalisia vasta-aineita CD44V6 vastaan
ATE86634T1 (de) Humaner monoklonaler antikoerper gegen pseudomonas aeruginosagegen pseudomonas aeruginosa produzierende hybridomen.
DE69320192D1 (de) Monoklonaler antikörper gegen den extravillösen trophoblast
DE69324928D1 (de) Monoklonaler antikörper

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 10 (VIII), 10 (IX), 18 (III) E 24 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.